Contact
Please use this form to send email to PR contact of this press release:
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
TO:
Please use this form to send email to PR contact of this press release:
Turning Point Therapeutics Granted Fast-Track Designation for Repotrectinib in NTRK-Positive TKI-Pretreated Advanced Solid Tumors
TO: